The "Double-Limited" Challenge: Is ASD Always the Answer?

For this compound, we need to take a systematic approach. The key question is whether absorption is primarily limited by solubility or by permeability.

If enhancement of solubility does not lead to improved bioavailability, the compound is likely permeability-limited. In this case, an amorphous solid dispersion (ASD), which primarily enhances apparent solubility and dissolution rate, may not provide meaningful benefit.

If solubility enhancement results in improved bioavailability, the compound is likely solubility-limited. In that scenario, ASD represents a rational and worthwhile strategy. Other enabling approaches may also be considered, such as salt formation or lipid-based formulations.

If it is not yet clear whether the compound is solubility-limited or permeability-limited, ASD may still be explored as part of a broader formulation screening strategy, alongside other enabling technologies.

However, its selection should be guided by experimental evidence rather than assumption.